Iterum Therapeutics Statistics
Share Statistics
Iterum Therapeutics has 27.52M shares outstanding. The number of shares has increased by 105.06% in one year.
| Shares Outstanding | 27.52M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 21.18% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 26.76M |
| Failed to Deliver (FTD) Shares | 113.13K |
| FTD / Avg. Volume | 3.8% |
Short Selling Information
The latest short interest is 2.53M, so 9.2% of the outstanding shares have been sold short.
| Short Interest | 2.53M |
| Short % of Shares Out | 9.2% |
| Short % of Float | 9.46% |
| Short Ratio (days to cover) | 0.46 |
Valuation Ratios
The PE ratio is -0.67 and the forward PE ratio is -2.24.
| PE Ratio | -0.67 |
| Forward PE | -2.24 |
| PS Ratio | 0 |
| Forward PS | 2 |
| PB Ratio | -3.99 |
| P/FCF Ratio | -0.65 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Iterum Therapeutics.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.89, with a Debt / Equity ratio of -2.96.
| Current Ratio | 1.89 |
| Quick Ratio | 1.89 |
| Debt / Equity | -2.96 |
| Total Debt / Capitalization | 151.01 |
| Cash Flow / Debt | -2.07 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 5.99% and return on capital (ROIC) is -384.28%.
| Return on Equity (ROE) | 5.99% |
| Return on Assets (ROA) | -1.46% |
| Return on Capital (ROIC) | -384.28% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.74M |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 613.00K |
| Effective Tax Rate | -0.02 |
Stock Price Statistics
The stock price has increased by -4.48% in the last 52 weeks. The beta is 2.25, so Iterum Therapeutics's price volatility has been higher than the market average.
| Beta | 2.25 |
| 52-Week Price Change | -4.48% |
| 50-Day Moving Average | 1.75 |
| 200-Day Moving Average | 1.41 |
| Relative Strength Index (RSI) | 50.96 |
| Average Volume (20 Days) | 2.98M |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.75M |
| Operating Income | -47.47M |
| Net Income | -38.37M |
| EBITDA | -34.58M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.96 |
Balance Sheet
The company has 6.07M in cash and 18.96M in debt, giving a net cash position of -12.88M.
| Cash & Cash Equivalents | 6.07M |
| Total Debt | 18.96M |
| Net Cash | -12.88M |
| Retained Earnings | -461.30M |
| Total Assets | 15.92M |
| Working Capital | -2.85M |
Cash Flow
In the last 12 months, operating cash flow was -39.33M and capital expenditures -13.00K, giving a free cash flow of -39.34M.
| Operating Cash Flow | -39.33M |
| Capital Expenditures | -13.00K |
| Free Cash Flow | -39.34M |
| FCF Per Share | -3.04 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ITRM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -154.17% |
| FCF Yield | -74.66% |
Analyst Forecast
The average price target for ITRM is $5, which is 160.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 160.4% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Aug 18, 2022. It was a backward split with a ratio of 1:15.
| Last Split Date | Aug 18, 2022 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -46.89 |
| Piotroski F-Score | 2 |